Therapeutic options in the management of acromegaly: focus on ...
Influence of lanreotide Autogel® on clinical manifestations ... usually by a carcinoid tumor of the lung or gastrointestinal tract (Biermasz et al 2007).
...... for long-term IGF-I normalization with Sandostatin-LAR in acromegaly.
..... A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721386/...
|
Hormonal crises following receptor radionuclide therapy with the ...
Long-acting somatostatin analogues (Sandostatin LAR, Lanreotide Autogel) were discontinued 1 .... VIPomas are associated with a well-defined clinical syndrome
... The carcinoid syndrome in patients with metastatic bronchial carcinoids is
.... The clinical presentation (symptoms and signs) of sporadic and familial ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=26...
|
Acromegaly
Sandostatin LAR Depot is a long-acting octreotide compound. ..... The acromegaly syndrome. Relation between clinical features, ..... A comparison of lanreotide
and octreotide LAR for treatment of acromegaly. ... Effectiveness and
tolerability of 3-year lanreotide autogel treatment in patients with acromegaly.
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697616/...
|
Somatostatin Analogs
Aetna considers lanreotide depot injection (Somatuline Depot) medically ... Carcinoid syndrome occurs when an abundance of hormones are produced from GI ...
such as LAR octreotide, slow-release lanreotide and lanreotide autogel ....
doxorubicin (Caelyx) combined with Sandostatin LAR as salvage treatment of small
...
http://www.aetna.com/cpb/medical/data/600_699/0693.html...
|
1750-1172-3-17 1750-1172 Review Acromegaly Chanson Philippe ...
Clinical symptoms such as dyspnea during exercise may be observed while the .... peripheral GHRH hypersecretion (pancreatic or bronchial carcinoid tumor) that
..... Effect of Sandostatin ® LAR ® on sleep apneoa in acromegaly: correlation
.... Comparison of octreotide acetate LAR and lanreotide SR in patients with ...
http://www.biomedcentral.com/content/download/xml/1750-1172-...
|
Newsletter 3
In addition to Sandostatin® LAR® (octreotide LAR), there is now a second ... Octreotide LAR. Lanreotide Depot. GH receptor antagonists. Pegvisomant ...
jection with Somatuline ® Autogel a recently approved drug for treatment of
Acromegaly ... Her clinical interests include pituitary tumors, Cushing's
syndrome, ...
http://www.mdanderson.org/education-and-research/departments...
|
Acromegaly
Clinical symptoms such as dyspnea during exercise may be observed while the .... McCune-Albright syndrome, which is associated with multiple fibrous bone
dysplasia, ...... Torres E. Comparison of octreotide acetate LAR and lanreotide
SR in ... of lanreotide (lanreotide Autogel) in the management of acromegaly.
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2459162/...
|
Microsoft PowerPoint - DIFF.V1.site internet
or after clinical trials but never be launched on the market or be ..... In-situ Formation of Taspoglutide depot from Liquid Sustained Release Formulation ...
Injection technique. Sandostatin LAR®. Somatuline® Autogel® ..... Efficacy of
combined treatment with lanreotide and ..... syndrome. Obesity. Healthy ...
http://www.ipsen.com/articles/investorrelations/roadshows/20...
|
>-1 -1 . -1 , -1 : -1 - Charité - Universitätsmedizin Berlin: Charité
Comparison 3400352 Conservative -1 Unstable -1 Inhibior 3400362 Tirofiban. ...... Lanreotide -1 Beiske 3624934 Johamma 3624944 Margarete 3624954
Gerstenhauer .... cal -1 Erythrocyte -1 lacunar 3634800 cardiovascu 3634810 lar
-1 RBC 3634820 ... rezeptoren -1 metastatized 3637028 attain 3637038 sandostatin
-1 thereon ...
http://www.charite.de/forschungsberichte/FOB_2003-2005/engli...
|
registration document
the treatment of symptoms associated with neuroendocrine ... particularly of a carcinoid type, by inhibiting the over- ... Depot (lanreotide) Injection 60, 90
and 120 mg in the United. States. ... Autogel®'s main rivals are (i) Sandostatin
®. LAR Depot (a somatostatin analogue called octreotide) ...
http://www.ipsen.com/articles/investorrelations/publications...
|
